- Home
- RIGL
as 05-20-2024 4:00pm EST
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 166.7M | IPO Year: | 2000 |
| Target Price: | $5.81 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.11 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.71 - $1.77 | Next Earning Date: | 05-07-2024 |
| Revenue: | $120,346,000 | Revenue Growth: | -7.12% |
| Revenue Growth (this year): | 30.02% | Revenue Growth (next year): | 28.98% |
Share on Social Networks:
Stock Insider Trading Activity of Rigel Pharmaceuticals Inc. (RIGL)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Santos David A | RIGL | EVP, Chief Commercial Officer | Feb 2 '24 | Sell | $1.13 | 5,601 | $6,329.13 | 358,011 | SEC Form 4 |
| Santos David A | RIGL | EVP, Chief Commercial Officer | Feb 2 '24 | Sell | $1.14 | 8,918 | $10,166.52 | 349,093 | SEC Form 4 |
| Schorno Dean L | RIGL | EVP & Chief Financial Officer | Feb 2 '24 | Sell | $1.13 | 5,601 | $6,326.89 | 409,918 | SEC Form 4 |
| Schorno Dean L | RIGL | EVP & Chief Financial Officer | Feb 2 '24 | Sell | $1.14 | 7,027 | $8,010.78 | 402,891 | SEC Form 4 |
Latest Rigel Pharmaceuticals Inc. News
RIGL Breaking Stock News: Dive into RIGL Ticker-Specific Updates for Smart Investing
Zacks
10 days ago
Rigel (RIGL) Upgraded to Buy: Here's What You Should Know
Simply Wall St.
10 days ago
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Analysts Are Pretty Bullish On The Stock After Recent Results
Insider Monkey
12 days ago
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q1 2024 Earnings Call Transcript
GuruFocus.com
13 days ago
Rigel Pharmaceuticals Inc (RIGL) Q1 2024 Earnings Call Transcript Highlights: Strategic Moves ...
Zacks
13 days ago
Rigel Pharmaceuticals (RIGL) Reports Q1 Loss, Lags Revenue Estimates
Associated Press Finance
13 days ago
Rigel: Q1 Earnings Snapshot
PR Newswire
13 days ago
Rigel Reports First Quarter 2024 Financial Results and Provides Business Update
Zacks
18 days ago